Introduction and Company Overview Founded in 1998, Gan & Lee Pharmaceuticals (SHSE: 603087) is a Chinese biopharma company specializing in

Taiwan's biotech industry reached record output in 2025 as the island leverages semiconductor-era manufacturing expertise to build Asia's next pharmaceutical hub. This analysis examines the companies, regulatory frameworks, CDMO expansion, and investment ecosystem shaping the sector's trajectory.

Pharmaceutical mergers and acquisitions face unprecedented antitrust scrutiny in the United States and European Union. Regulators no longer focus solely

Clinical trial liability insurance represents a critical but often underestimated cost in drug development. The global clinical trials market reached

Biotech deal activity surges in year-end 2025 window The final week of 2025 and opening days of 2026 delivered over

Sublicense royalties have become an important feature in pharmaceutical royalty financing deals, especially as biotech firms and pharma companies seek

In the basement of a nondescript office building in South San Francisco, the fluorescent lights still hummed over empty lab

Six thoughtful (and slightly cheeky) resolutions for biotech investors, executives, and scientists to make 2026 a breakthrough year.

What Is a Revenue Interest Purchase and Sale Agreement? A Revenue Interest Purchase and Sale Agreement is a contractual financing

In restructuring parlance, a stalking horse bid is an initial binding offer on a bankrupt debtor's assets, made by a chosen buyer, that sets the floor price for an auction.